OBJECTIVE: To define relationships of androgen excesses to cancer risk. DESIGN: Retrospective cohort study. SETTING: Five large infertility practices. PATIENT(S): Among 12,193 women evaluated for infertility during 1965-1988 and traced for cancer incidence through 1999, 2,560 had androgen excess or menstrual disorders; among these, 412 met established criteria for polycystic ovary syndrome. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Cancer incidence. Derivation of standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for cancer risk comparisons with the general population and rate ratios (RRs) for comparisons with other infertility patients. RESULT(S): Androgen excess/menstrual disorder patients showed significant SIRs for breast (1.31; 95% CI, 1.05-1.62) and uterine (2.02; 95% CI, 1.13-3.34) cancers and melanoma (1.96; 95% CI, 1.12-3.18). Significant associations for breast and uterine cancers were restricted to primary infertility patients (respective SIRs of 1.53 and 3.48). After adjustment for other cancer predictors, the only excess risk was for uterine cancer among primary infertility patients. Compared with women with secondary infertility and no androgen excess/menstrual disorder, those with primary infertility and a disorder had an RR of 1.88 (95% CI, 0.82-4.32). Cancer risks among the women with polycystic ovary syndrome or androgen excess disorders appeared to be similar to those in the more comprehensive group. CONCLUSION(S): Previous findings linking androgen excess disorders to elevated uterine cancer risks might largely reflect underlying risk profiles. Published by Elsevier Inc.
OBJECTIVE: To define relationships of androgen excesses to cancer risk. DESIGN: Retrospective cohort study. SETTING: Five large infertility practices. PATIENT(S): Among 12,193 women evaluated for infertility during 1965-1988 and traced for cancer incidence through 1999, 2,560 had androgen excess or menstrual disorders; among these, 412 met established criteria for polycystic ovary syndrome. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Cancer incidence. Derivation of standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for cancer risk comparisons with the general population and rate ratios (RRs) for comparisons with other infertilitypatients. RESULT(S): Androgen excess/menstrual disorderpatients showed significant SIRs for breast (1.31; 95% CI, 1.05-1.62) and uterine (2.02; 95% CI, 1.13-3.34) cancers and melanoma (1.96; 95% CI, 1.12-3.18). Significant associations for breast and uterine cancers were restricted to primary infertilitypatients (respective SIRs of 1.53 and 3.48). After adjustment for other cancer predictors, the only excess risk was for uterine cancer among primary infertilitypatients. Compared with women with secondary infertility and no androgen excess/menstrual disorder, those with primary infertility and a disorder had an RR of 1.88 (95% CI, 0.82-4.32). Cancer risks among the women with polycystic ovary syndrome or androgen excess disorders appeared to be similar to those in the more comprehensive group. CONCLUSION(S): Previous findings linking androgen excess disorders to elevated uterine cancer risks might largely reflect underlying risk profiles. Published by Elsevier Inc.
Authors: I Konishi; M Koshiyama; M Mandai; H Kuroda; S Yamamoto; K Nanbu; T Komatsu; K Matsushita; C V Rao; T Mori Journal: Gynecol Oncol Date: 1997-05 Impact factor: 5.482
Authors: G Iatrakis; S Zervoudis; A Saviolakis; M Troulos; E Antoniou; A Sarantaki; K Lykeridou; G Kourounis Journal: Eur J Gynaecol Oncol Date: 2006 Impact factor: 0.196
Authors: Louise A Brinton; Bert Scoccia; Kamran S Moghissi; Carolyn L Westhoff; Michelle D Althuis; Jerome E Mabie; Emmet J Lamb Journal: Hum Reprod Date: 2004-06-24 Impact factor: 6.918
Authors: Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich Journal: Endocr Relat Cancer Date: 2012-11-09 Impact factor: 5.678
Authors: Jayeon Kim; Jennifer E Mersereau; Nikhil Khankari; Patrick T Bradshaw; Lauren E McCullough; Rebecca Cleveland; Sumitra Shantakumar; Susan L Teitelbuam; Alfred I Neugut; Ruby T Senie; Marilie D Gammon Journal: Cancer Causes Control Date: 2016-01-21 Impact factor: 2.506
Authors: Jane H Zhou; Kevin B Kim; Jeffrey N Myers; Patricia S Fox; Jing Ning; Roland L Bassett; Hassan Hasanein; Victor G Prieto Journal: Am J Dermatopathol Date: 2014-01 Impact factor: 1.533
Authors: Holly R Harris; Kara L Cushing-Haugen; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Lorna Rodriguez; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Sara Lindström; Kathryn L Terry Journal: Int J Epidemiol Date: 2019-06-01 Impact factor: 9.685
Authors: Maria M Szwarc; Ramakrishna Kommagani; Jae-Wook Jeong; San-Pin Wu; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley; Francesco J DeMayo; John P Lydon Journal: PLoS One Date: 2014-06-06 Impact factor: 3.240
Authors: H P Yang; L S Cook; E Weiderpass; H-O Adami; K E Anderson; H Cai; J R Cerhan; T V Clendenen; A S Felix; C M Friedenreich; M Garcia-Closas; M T Goodman; X Liang; J Lissowska; L Lu; A M Magliocco; S E McCann; K B Moysich; S H Olson; S Petruzella; M C Pike; S Polidoro; F Ricceri; H A Risch; C Sacerdote; V W Setiawan; X O Shu; A B Spurdle; B Trabert; P M Webb; N Wentzensen; Y-B Xiang; Y Xu; H Yu; A Zeleniuch-Jacquotte; L A Brinton Journal: Br J Cancer Date: 2015-02-17 Impact factor: 9.075